Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Biofrontera Equity Warrants 27th Oct 2026 BFRIW

Biofrontera Inc. is a biopharmaceutical company. The Company is focused on commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company's licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial... see more

Recent & Breaking News (NDAQ:BFRIW)

Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update

GlobeNewswire March 21, 2025

Biofrontera Inc. Announces Completion of Patient Enrollment in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Actinic Keratoses on the Extremities, Neck and Trunk

GlobeNewswire March 18, 2025

Biofrontera Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 21, 2025

GlobeNewswire March 11, 2025

Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

GlobeNewswire January 8, 2025

Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market

GlobeNewswire December 23, 2024

Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note

GlobeNewswire November 22, 2024

Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update

GlobeNewswire November 13, 2024

Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

GlobeNewswire October 31, 2024

Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

GlobeNewswire October 14, 2024

FDA Approves Use of Up To Three Tubes of Biofrontera Inc.'s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment

GlobeNewswire October 7, 2024

Biofrontera Inc. Reports Second Quarter 2024 Financial Results and Provides a Business Update

GlobeNewswire August 14, 2024

Biofrontera Announces the Launch of a New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp

GlobeNewswire June 24, 2024

Biofrontera Inc. Announces Voting Results from 2022 Annual Meeting of Stockholders

GlobeNewswire December 16, 2022

Biofrontera Inc. to Participate in Benchmark's 11th Annual Discovery One-on-One Investor Conference

GlobeNewswire November 30, 2022

BIOFRONTERA INC. TO PARTICIPATE IN RENMARK'S VIRTUAL NON-DEAL ROADSHOW SERIES ON WEDNESDAY, NOVEMBER 30, MONDAY, DECEMBER 5, FRIDAY, DECEMBER 9, AND MONDAY, DECEMBER 19 2022

GlobeNewswire November 28, 2022

Biofrontera to Launch Phase 3 Clinical Study Evaluating Ameluz®-PDT for the Treatment of Actinic Keratosis on the Extremities, Neck and Trunk

GlobeNewswire November 21, 2022

Biofrontera Inc. Reports Third Quarter 2022 Financial Results and Provides a Business Update

GlobeNewswire November 14, 2022

Biofrontera Inc. to Report Third Quarter Financial Results on November 14, 2022

GlobeNewswire November 10, 2022

Biofrontera Inc. Fully Exercises Recently Acquired Options to Purchase Shares of Biofrontera AG

GlobeNewswire November 8, 2022

Biofrontera Inc. Enters into Agreements to Purchase Options of Biofrontera AG

GlobeNewswire October 31, 2022